Pathological brain ageing: evaluation of the efficacy of a pharmacological aid.
The efficacy of a molecule active at metabolic, neurotransmitter and membrane levels was evaluated in a group of 20 patients with typical involutional symptoms, who came under the care of the rehabilitation therapist for their concomitant decrease of motor activities. All subjects were treated with 1.5 g/day L-acetylcarnitine per os for 6 months, and subjected to the evaluation of cognitive ability (MMS), depression (HDRS), and behavioral and self-sufficiency performances (SCAG), at baseline (t0), after 90 days (t1), and after 180 days (t2). Whereas the basal evaluation showed disorders at all levels, the treatment gave a statistically significant improvement of all performances at both t1 and t2, achieving an effective recovery of the patients' quality of life, an improved participation in family and social life, and a diminished inertness in motor activity, which was the reason why they were studied.
Guarnaschelli
C
C
Salvatore Maugeri Foundation, Work and Rehabilitation Clinic, IRCCS, Montescano (PV), Italy.
Fugazza
G
G
Pistarini
C
C
D000108:Acetylcarnitine / Q000627:therapeutic use*; D000368:Aged; D000375:Aging; D002331:Carnitine / Q000031:analogs & derivatives*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D019965:Neurocognitive Disorders / Q000188:drug therapy* / Q000523:psychology; D011569:Psychiatric Status Rating Scales; D011788:Quality of Life
D000108:Acetylcarnitine; D002331:Carnitine